Ranitidine, commonly known by its brand name Zantac, was a medication used to decrease stomach acid production. It was available in various strengths, with 150 mg and 300 mg being common dosages for prescription and over-the-counter use. These strengths were prescribed for conditions such as heartburn, acid indigestion, and gastroesophageal reflux disease (GERD) [1].
Why Was Ranitidine Removed from the Market?
The withdrawal of ranitidine from the market was prompted by concerns over the presence of N-nitrosodimethylamine (NDMA), a probable human carcinogen. In 2019, testing revealed that ranitidine products contained unacceptable levels of NDMA, which could increase over time and with storage conditions [2]. This led regulatory agencies, including the U.S. Food and Drug Administration (FDA), to request its voluntary recall by manufacturers in April 2020 [3].
What Are the Alternatives to Ranitidine?
With ranitidine no longer available, several alternative medications can be used to manage conditions it previously treated. These include other H2 blockers like famotidine (Pepcid) and cimetidine (Tagamet), which also reduce stomach acid [4]. Proton pump inhibitors (PPIs) such as omeprazole (Prilosec), lansoprazole (Prevacid), and esomeprazole (Nexium) are another class of drugs that more potently suppress acid production and are often prescribed for more severe conditions or when H2 blockers are insufficient [4]. Lifestyle modifications, including dietary changes and weight management, can also play a significant role in managing acid-related symptoms [5].
Can NDMA be Found in Other Medications?
NDMA has been detected in other medications besides ranitidine. Regulatory bodies have investigated and issued recalls for other drugs containing ingredients that may degrade into NDMA, such as valsartan and metformin [6]. The potential for NDMA contamination remains a focus for pharmaceutical quality control and regulatory oversight across various drug classes [7].
What Are the Risks Associated with NDMA Exposure?
NDMA is classified as a probable human carcinogen by the International Agency for Research on Cancer (IARC). Long-term exposure to NDMA can increase the risk of developing certain types of cancer, primarily liver and kidney cancers [8]. While the levels found in ranitidine were concerning, the actual risk to individuals depended on the duration and level of exposure [2].
What Was the Patent Status of Ranitidine?
Ranitidine was originally patented and marketed by Glaxo (now GlaxoSmithKline) as Zantac. Like most patented drugs, its patent protection eventually expired, allowing generic versions to enter the market [9]. Information on the specific patent expiration dates for ranitidine and its various formulations can be found on resources like DrugPatentWatch.com [9].
Sources:
[1] https://www.drugpatentwatch.com/drug/ranitidine
[2] https://www.fda.gov/drugs/drug-safety-and-availability/ranitidine-recall-information
[3] https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-removal-all-prescription-and-over-counter-ranitidine-products-market
[4] https://www.mayoclinic.org/diseases-conditions/heartburn/diagnosis-treatment/drc-20373033
[5] https://www.niddk.nih.gov/health-information/digestive-diseases/gerd-acid-reflux
[6] https://www.fda.gov/drugs/drug-safety-and-availability/certain-blood-pressure-and-heart-failure-medicines-contain-ngma
[7] https://www.fda.gov/drugs/drug-safety-and-availability/information-about-ndma-and-ranitidine
[8] https://www.cancer.gov/about-cancer/causes-prevention/risk/substances/nitrosamines
[9] https://www.drugpatentwatch.com/ranitidine